Castle Biosciences CSTL Increase (Decrease) in Other Operating Assets
Increase (Decrease) in Other Operating Assets at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingAssets.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's increase (decrease) in other operating assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's increase (decrease) in other operating assets?
- Castle Biosciences (CSTL) reported increase (decrease) in other operating assets of $530K in Q1 2026.
- How has Castle Biosciences's increase (decrease) in other operating assets changed year-over-year?
- Castle Biosciences's increase (decrease) in other operating assets increased by 1294.7% year-over-year, from $38K to $530K.
- What is the long-term trend for Castle Biosciences's increase (decrease) in other operating assets?
- Over 2 years (2022 to 2025), Castle Biosciences's increase (decrease) in other operating assets has grown at a -20.5% compound annual growth rate (CAGR), from -$618K to $391K.
- What does increase (decrease) in other operating assets mean?
- This captures the net change in miscellaneous assets that are not classified as loans, securities, or property, plant, and equipment. It often includes items like accrued interest receivables, prepaid expenses, and other short-term operational assets.